AbCellera Biologics (NASDAQ:ABCL) Announces Earnings Results

AbCellera Biologics (NASDAQ:ABCL) announced its quarterly earnings results on Wednesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.04), FiscalAI reports. AbCellera Biologics had a negative return on equity of 17.22% and a negative net margin of 248.83%.The company had revenue of $4.05 million during the quarter, compared to analysts’ expectations of $7.85 million.

Here are the key takeaways from AbCellera Biologics’ conference call:

• ABCL635 enrollment and dosing were completed ahead of schedule, with top-line Phase I data in post-menopausal women expected shortly. Management views a clean safety profile and efficacy comparable to approved small-molecule treatments as key success criteria.
• AbCellera announced T-cell engager collaborations with Vertex and Jazz that provide more than $110 million in upfront payments, with potential downstream payments exceeding $2 billion under the Jazz agreement and tiered royalties on sales.
• ABCL688 and ABCL386 remain in IND-enabling work and are expected to enter Phase I/II studies in 2027, while the ABCL575 Phase I trial is on track for a Q4 readout; the company currently does not plan to develop ABCL575 beyond Phase I.
• Second-quarter revenue fell to approximately $4 million from $17 million a year earlier, while the net loss widened to about $55 million, or $0.18 per share, as research and development spending increased to support internal programs.
• AbCellera ended the quarter with approximately $567 million in cash and marketable securities, plus roughly $110 million in committed government funding, which management believes is sufficient to fund at least three years of pipeline investment.

AbCellera Biologics Price Performance

Shares of ABCL stock opened at $6.53 on Friday. The company has a market capitalization of $1.99 billion, a P/E ratio of -12.09 and a beta of 1.20. The company’s 50-day simple moving average is $6.21 and its two-hundred day simple moving average is $4.67. AbCellera Biologics has a one year low of $2.74 and a one year high of $8.44.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ABCL. JonesTrading assumed coverage on AbCellera Biologics in a research report on Friday, April 10th. They set a “buy” rating and a $11.00 price objective for the company. Benchmark raised shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Tuesday, July 7th. Stifel Nicolaus lifted their price objective on shares of AbCellera Biologics from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Friday, July 17th. Finally, Cantor Fitzgerald raised their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $9.40.

Institutional Investors Weigh In On AbCellera Biologics

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of AbCellera Biologics during the 4th quarter worth $26,938,000. Two Sigma Investments LP lifted its stake in AbCellera Biologics by 25.9% in the third quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company’s stock worth $26,031,000 after acquiring an additional 1,064,290 shares during the period. Goldman Sachs Group Inc. grew its holdings in AbCellera Biologics by 1,636.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,344,485 shares of the company’s stock worth $14,858,000 after acquiring an additional 4,094,268 shares in the last quarter. Bank of America Corp DE increased its position in AbCellera Biologics by 977.8% during the 3rd quarter. Bank of America Corp DE now owns 2,418,304 shares of the company’s stock valued at $12,164,000 after purchasing an additional 2,193,939 shares during the period. Finally, Tudor Investment Corp ET AL increased its position in AbCellera Biologics by 146.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 1,796,010 shares of the company’s stock valued at $6,142,000 after purchasing an additional 1,065,888 shares during the period. 61.42% of the stock is owned by institutional investors.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.